Table 1 The demographics and clinical characteristics of the subjects
| Â | Primary cohort | PSM cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Experimental Group | Control Group | B | P value | Experimental Group | Control Group | B | P value |
N | 136 | 169 | Â | Â | 81 | 123 | Â | Â |
Age (years), M (P25, P75) | 60(53,66) | 69(64,72) | -8.983 |  < 0.001 | 66(61,68) | 66(63,70) | -2.225 | 0.026 |
Sex | Â | Â | 9.885 | 0.002 | Â | Â | 0.014 | 0.905 |
 Male, n(%) | 81(59.6) | 129(76.3) |  |  | 56(69.1) | 86(69.9) |  |  |
 Female, n(%) | 55(40.4) | 40(23.7) |  |  | 25(30.9) | 37(30.1) |  |  |
Hypertension, n(%) | Â | Â | 2.966 | 0.085 | Â | Â | 0.035 | 0.851 |
 Yes | 72(52.9) | 106(62.7) |  |  | 47(58) | 73(59.3) |  |  |
 No | 64(47.1) | 63(37.3) |  |  | 34(42) | 50(40.7) |  |  |
Diabetes, n(%) | Â | Â | 2.044 | 0.153 | Â | Â | 0.137 | 0.712 |
 Yes | 43(31.6) | 41(24.3) |  |  | 25(30.9) | 3528.5) |  |  |
 No | 93(68.4) | 128(75.7) |  |  | 56(69.1) | 88(71.5) |  |  |
Smoking history, n(%) | Â | Â | 1.741 | 0.419 | Â | Â | 2.278 | 0.320 |
 No smoking | 74(54.4) | 80(47.3) |  |  | 39(48.1) | 55(44.7) |  |  |
 Quit smoking | 24(17.6) | 31(18.3) |  |  | 18(22.2) | 20(16.3) |  |  |
 Still smoking | 38(27.9) | 58(34.3) |  |  | 24(29.6) | 48(39) |  |  |
Drinking history, n(%) | Â | Â | 2.990 | 0.224 | Â | Â | 2.843 | 0.241 |
 No drinking | 75(55.1) | 77(45.6) |  |  | 46(56.8) | 59(48) |  |  |
 Quit drinking | 7(5.1) | 13(7.7) |  |  | 3(3.7) | 11(8.9) |  |  |
 Still drinking | 54(39.7) | 79(46.7) |  |  | 32(39.5) | 53(43.1) |  |  |
NT-proBNP, M (P25, P75) | 1370(656.13,2681) | 1519(703.9,2920) | -0.696 | 0.486 | 1571 (803.2, 2752) | 1551 (775,2749) | -0.175 | 0.861 |
CTNI, M (P25, P75) | 229.98(42.56,1877.78) | 469.99(20.76,4719.5) | -1.033 | 0.302 | 223.4 (40.72) | 714.52 (19.3,4894) | -1.582 | 0.114 |
β Receptor blocker, n(%) |  |  | 0.554 | 0.457 |  |  | 2.831 | 0.092 |
 Yes | 125(91.9) | 159(94.1) |  |  | 71(87.7) | 116(94.3) |  |  |
 No | 11(8.1) | 10(5.9) |  |  | 10(12.3) | 7(5.7) |  |  |
Spironolactone, n(%) | Â | Â | 1.116 | 0.291 | Â | Â | 0.188 | 0.665 |
 Yes | 100(73.5) | 133(78.7) |  |  | 64(79) | 94(76.4) |  |  |
 No | 36(26.5) | 36(21.3) |  |  | 17(21) | 29(23.6) |  |  |
Statins, n(%) | Â | Â | 0.088 | 0.767 | Â | Â | 0.105 | 0.746 |
 Yes | 132(97.1) | 163(96.4) |  |  | 79(97.5) | 119(96.7) |  |  |
 No | 4(2.9) | 6(3.6) |  |  | 2(2.5) | 4(3.3) |  |  |
LVEF(during hospitalization), M (P25, P75) | 0.33(0.28,0.38) | 0.34(0.29,0.4) | -1.180 | 0.238 | 0.35 (0.3, 0.39) | 0.33 (0.29,0.4) | -0.217 | 0.828 |
LVEF(follow-up), M (P25, P75) | 0.41(0.37,0.46) | 0.4(0.36,0.44) | -3.102 | 0.002 | 0.4 (0.36,0.46) | 0.4 (0.36,0.44) | -0.817 | 0.414 |
LVEF(change), n(%) | Â | Â | 0.213 | 0.899 | Â | Â | 5.782 | 0.056 |
 Lower | 46(33.8) | 53(31.4) |  |  | 37(45.7) | 36(29.3) |  |  |
 Unchanged | 6(4.4) | 8(4.7) |  |  | 3(3.7) | 7(5.7) |  |  |
 Higher | 84(61.8) | 108(63.9) |  |  | 41(50.6) | 80(65) |  |  |
LVEF(Improvement rate), M (P25, P75) | 0.26 (-0.03, 0.62) | 0.11 (-0.03, 0.39) | -2.513 | 0.012 | 0.027 (-0.05,0.55) | 0.114 (-0.03,0.39) | -0.124 | 0.902 |